Get the Stockscreener App
4.82
0.62%
-0.03
After Hours:
4.86
0.04
+0.83%
Nuvation Bio Inc stock is traded at $4.82, with a volume of 1.81M.
It is down -0.62% in the last 24 hours and up +8.56% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$4.85
Open:
$4.86
24h Volume:
1.81M
Relative Volume:
0.36
Market Cap:
$1.68B
Revenue:
$62.90M
Net Income/Loss:
$-204.63M
P/E Ratio:
-8.0374
EPS:
-0.5997
Net Cash Flow:
$-181.78M
1W Performance:
+6.40%
1M Performance:
+8.56%
6M Performance:
+27.85%
1Y Performance:
+138.61%
1-Day Range:
$4.77
$4.93
1-Week Range:
$4.375
$4.93
52-Week Range:
$1.57
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.82 | 1.69B | 62.90M | -204.63M | -181.78M | -0.5997 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Nuvation Bio Inc. (NUVB) turns bullish amid positive regulatory trajectory in Europe - MSN
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo - MSN
Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks - Insider Monkey
Nuvation Bio Executive Share Sale: CRO Kerry Wentworth Sells 200,000 SharesNews and Statistics - IndexBox
Market Fear: Is Nuvation Bio Inc stock undervalued right nowGap Down & Weekly Sector Rotation Insights - baoquankhu1.vn
Risk Hedge: Is Nuvation Bio Inc stock undervalued right nowWeekly Market Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB) - Yahoo Finance
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB) - The Motley Fool
Wedbush Bullish on Nuvation Bio (NUVB) As NUVB Expands Safusidenib Rights - Insider Monkey
Nuvation Bio (NUVB) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Aug Big Picture: Is Nuvation Bio Inc stock a hidden gemWeekly Stock Analysis & Daily Profit Maximizing Tips - baoquankhu1.vn
Nuvation Bio Inc. (NUVB): Billionaire David Abrams has a long-term bet on this stock - MSN
NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Nuvation Bio (NUVB) - The Globe and Mail
Nuvation Bio officer Wentworth sells $903k in shares By Investing.com - Investing.com Canada
Nuvation Bio officer Wentworth sells $903k in shares - Investing.com
Nuvation Bio stock rating reaffirmed at Buy by Truist Securities - Investing.com Australia
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $4.51 - Moomoo
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nuvation Bio Inc. (NUVB) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nuvation Bio Inc. (NUVB) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Nuvation Bio Inc. (NUVB) and Eisai get EMA validation for taletrectinib - MSN
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Nuvation Bio Inc. (NUVB) Turns Bullish amid Positive Regulatory Trajectory in Europe - Yahoo Finance
[144] Nuvation Bio Inc. SEC Filing - Stock Titan
RBC Capital raises Nuvation Bio stock price target on glioma potential - Investing.com Canada
RBC Capital raises Nuvation Bio stock price target on glioma potential By Investing.com - in.investing.com
RBC Raises Price Target on Nuvation Bio to $20 From $13, Keeps Outperform, Speculative Risk - marketscreener.com
JPMorgan Chase & Co. Purchases 557,656 Shares of Nuvation Bio Inc. $NUVB - MarketBeat
Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB - MarketBeat
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-04-05 | Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NYSE:NUVB | Press Release - Stockhouse
10 Best Multibagger Penny Stocks to Invest In - insidermonkey.com
Aug Reactions: Is Nuvation Bio Inc exposed to currency risks2026 Price Momentum & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity? - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bullish analyst sentiment on Nuvation Bio (NUVB) amid early commercialization progress - MSN
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Shareholders to Inquire about Securities Investigation | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio Inc. (NUVB) amends protocol on safusidenib trials in astrocytoma - MSN
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact L - GuruFocus
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nuvation Bio Inc. (NUVB) And Encourages Investors to Connect - ACCESS Newswire
Nuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from Wedbush - marketbeat.com
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):